Track EPO patent oppositions in real-time. Monitor which companies are filing challenges, identify patents under dispute, and analyze opposition trends across industries.
Recent patent oppositions filed at the EPO, providing crucial intelligence for R&D strategies, competitive analysis, and litigation planning. The data is updated on a weekly basis to ensure you have access to the most current information.
| Patent Number | Title | Applicant | Opposition Date | Opposition Name |
|---|---|---|---|---|
Get alerts for new patent oppositions | ||||
| A Filler Compound And Use Of A Filler Compound | SAINT GOBAIN | Aug 5, 2026 | KNAUF INSULATION + 5 more oppositions | |
| A Filler Compound And Use Of A Filler Compound | SAINT GOBAIN | Aug 4, 2026 | AECHTER + 5 more oppositions | |
| A Filler Compound And Use Of A Filler Compound | SAINT GOBAIN | Aug 4, 2026 | AKZO NOBEL + 5 more oppositions | |
| A Filler Compound And Use Of A Filler Compound | SAINT GOBAIN | Aug 3, 2026 | DANA LIM + 5 more oppositions | |
| Method Of Treating Cancer Using Immune Checkpoint Inhibitor; Antibody That Binds To Programmed Death-1 Receptor (Pd-1) Or Programmed Death Ligand 1 (Pd-L1) | BRISTOL MYERS SQUIBB | Jul 29, 2026 | STORZ + 8 more oppositions | |
| Method Of Treating Cancer Using Immune Checkpoint Inhibitor; Antibody That Binds To Programmed Death-1 Receptor (Pd-1) Or Programmed Death Ligand 1 (Pd-L1) | BRISTOL MYERS SQUIBB | Jul 28, 2026 | BRAND MURRAY FULLER + 8 more oppositions | |
| Method Of Treating Cancer Using Immune Checkpoint Inhibitor; Antibody That Binds To Programmed Death-1 Receptor (Pd-1) Or Programmed Death Ligand 1 (Pd-L1) | BRISTOL MYERS SQUIBB | Jul 28, 2026 | DEVA HOLDING + 8 more oppositions | |
| Method Of Treating Cancer Using Immune Checkpoint Inhibitor; Antibody That Binds To Programmed Death-1 Receptor (Pd-1) Or Programmed Death Ligand 1 (Pd-L1) | BRISTOL MYERS SQUIBB | Jul 28, 2026 | MAIWALD + 8 more oppositions | |
| Method Of Treating Cancer Using Immune Checkpoint Inhibitor; Antibody That Binds To Programmed Death-1 Receptor (Pd-1) Or Programmed Death Ligand 1 (Pd-L1) | BRISTOL MYERS SQUIBB | Jul 28, 2026 | PAJARO + 8 more oppositions | |
| Coated Paper And Paperboard Structures | WESTROCK MWV | Jul 27, 2026 | HIGHTONE MANAGEMENT + 1 more opposition | |
| Method Of Treating Cancer Using Immune Checkpoint Inhibitor; Antibody That Binds To Programmed Death-1 Receptor (Pd-1) Or Programmed Death Ligand 1 (Pd-L1) | BRISTOL MYERS SQUIBB | Jul 27, 2026 | GREINER + 8 more oppositions | |
| Glycolipid-Containing Cleansing Preparation Containing Micelles | BEIERSDORF | Jul 22, 2026 | APPLEYARD LEES + 1 more opposition | |
| Methods For Treating Cancer With Anti-Pd-1 Antibodies | MERCK SHARP & DOHME | Jul 22, 2026 | ABBOTT PRODUCTION OPERATIONS | |
| Method For Controlling A Synthesis Loop | CASALE | Jul 21, 2026 | TOPSOE + 1 more opposition | |
| Method Of Treating Cancer Using Immune Checkpoint Inhibitor; Antibody That Binds To Programmed Death-1 Receptor (Pd-1) Or Programmed Death Ligand 1 (Pd-L1) | BRISTOL MYERS SQUIBB | Jul 17, 2026 | POHLMAN + 8 more oppositions | |
| Methods Of Treating Hfpef Employing Dapagliflozin And Compositions Comprising The Same | ASTRAZENECA | Jul 15, 2026 | TEVA PHARMACEUTICALS + 3 more oppositions | |
| High-Bulk Ctmp | BILLERUD AKTIEBOLAG PUBL | Jul 14, 2026 | VALMET + 1 more opposition | |
| Method Of Treating Cancer Using Immune Checkpoint Inhibitor; Antibody That Binds To Programmed Death-1 Receptor (Pd-1) Or Programmed Death Ligand 1 (Pd-L1) | BRISTOL MYERS SQUIBB | Jul 13, 2026 | MANZER + 8 more oppositions | |
| High-Bulk Ctmp | BILLERUD AKTIEBOLAG PUBL | Jul 9, 2026 | STORA ENSO OYJ + 1 more opposition | |
| Hair Cosmetic Composition | KAO | Jul 9, 2026 | L'OREAL |